Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heterozygous familial hypercholesterolemia - Pipeline Review, H2 2020, provides an overview of the Heterozygous familial hypercholesterolemia (Metabolic Disorders) pipeline landscape.
Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder caused due to a mutation (alteration) of FH from one (affected) parent. Symptoms include xanthesmas, corneal arcus, aortic rupture and peripheral vascular disease. Risk factors include age, sex, smoking and hypertension, or associated lipid abnormalities such as low HDL-C levels, high TG levels, or presence of type III dyslipoproteinemia.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Heterozygous familial hypercholesterolemia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Heterozygous familial hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Heterozygous familial hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Heterozygous familial hypercholesterolemia (heFH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 2, 5, 2, 1 and 1 respectively.
Heterozygous familial hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heterozygous familial hypercholesterolemia - Pipeline Review, H2 2020, provides an overview of the Heterozygous familial hypercholesterolemia (Metabolic Disorders) pipeline landscape.
Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder caused due to a mutation (alteration) of FH from one (affected) parent. Symptoms include xanthesmas, corneal arcus, aortic rupture and peripheral vascular disease. Risk factors include age, sex, smoking and hypertension, or associated lipid abnormalities such as low HDL-C levels, high TG levels, or presence of type III dyslipoproteinemia.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Heterozygous familial hypercholesterolemia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Heterozygous familial hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Heterozygous familial hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Heterozygous familial hypercholesterolemia (heFH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 2, 5, 2, 1 and 1 respectively.
Heterozygous familial hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Heterozygous familial hypercholesterolemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Heterozygous familial hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Heterozygous familial hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Heterozygous familial hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Heterozygous familial hypercholesterolemia (Metabolic Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Heterozygous familial hypercholesterolemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Heterozygous familial hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Heterozygous familial hypercholesterolemia- Overview
Heterozygous familial hypercholesterolemia- Therapeutics Development
Heterozygous familial hypercholesterolemia- Therapeutics Assessment
Heterozygous familial hypercholesterolemia- Companies Involved in Therapeutics Development
Heterozygous familial hypercholesterolemia- Drug Profiles
Heterozygous familial hypercholesterolemia- Dormant Projects
Heterozygous familial hypercholesterolemia- Discontinued Products
Heterozygous familial hypercholesterolemia- Product Development Milestones
Appendix
Heterozygous familial hypercholesterolemia- Overview
Heterozygous familial hypercholesterolemia- Therapeutics Development
Heterozygous familial hypercholesterolemia- Therapeutics Assessment
Heterozygous familial hypercholesterolemia- Companies Involved in Therapeutics Development
Heterozygous familial hypercholesterolemia- Drug Profiles
Heterozygous familial hypercholesterolemia- Dormant Projects
Heterozygous familial hypercholesterolemia- Discontinued Products
Heterozygous familial hypercholesterolemia- Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by AD Pharmaceuticals Co Ltd, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Beijing Mabworks Biotech Co Ltd, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Daewoong Co Ltd, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Innovent Biologics Inc, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Madrigal Pharmaceuticals Inc, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by NeuroBo Pharmaceuticals Inc, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Novartis AG, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Shanghai Junshi Bioscience Co Ltd, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Discontinued Products, H2 2020
Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by AD Pharmaceuticals Co Ltd, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Beijing Mabworks Biotech Co Ltd, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Daewoong Co Ltd, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Innovent Biologics Inc, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Madrigal Pharmaceuticals Inc, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by NeuroBo Pharmaceuticals Inc, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Novartis AG, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Shanghai Junshi Bioscience Co Ltd, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects, H2 2020
Heterozygous familial hypercholesterolemia (heFH) - Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
